Literature DB >> 19398641

Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus.

Helio S Sader1, Paul R Rhomberg, Ronald N Jones.   

Abstract

Vancomycin and daptomycin MIC results for 1,800 randomly selected oxacillin (methicillin [meticillin])-resistant Staphylococcus aureus (MRSA) bloodstream isolates from nine U.S. hospitals (collected from 2002 to 2006) were determined by a reference broth microdilution (BMD) method using frozen-form panels with precise incremental dilutions and by the Etest technique. The Etest provided vancomycin and daptomycin MIC results that were consistently higher (0.5 to 1.5 log(2) dilution steps) than those provided by the reference BMD method. The dominant MRSA population (91.2% of MRSA isolates) would be categorized as vancomycin nonsusceptible by the MIC results from the Etest method if the susceptibility breakpoint was adjusted downward to < or =1 microg/ml, as suggested by clinical outcome studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398641      PMCID: PMC2704704          DOI: 10.1128/AAC.00093-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.

Authors:  Benjamin P Howden; Peter B Ward; Patrick G P Charles; Tony M Korman; Andrew Fuller; Philipp du Cros; Elizabeth A Grabsch; Sally A Roberts; Jenny Robson; Kerry Read; Narin Bak; James Hurley; Paul D R Johnson; Arthur J Morris; Barrie C Mayall; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-29       Impact factor: 9.079

Review 2.  Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.

Authors:  Ronald N Jones
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

3.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Authors:  Levita K Hidayat; Donald I Hsu; Ryan Quist; Kimberly A Shriner; Annie Wong-Beringer
Journal:  Arch Intern Med       Date:  2006-10-23

4.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.

Authors:  Donald I Hsu; Levita K Hidayat; Ryan Quist; Janet Hindler; Asa Karlsson; Anne Yusof; Annie Wong-Beringer
Journal:  Int J Antimicrob Agents       Date:  2008-08-12       Impact factor: 5.283

6.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Alex Soriano; Francesc Marco; José A Martínez; Elena Pisos; Manel Almela; Veselka P Dimova; Dolores Alamo; Mar Ortega; Josefina Lopez; Josep Mensa
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

7.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

8.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.

Authors:  Gregory Steinkraus; Roger White; Lawrence Friedrich
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

9.  Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

Authors:  Dawn M Sievert; James T Rudrik; Jean B Patel; L Clifford McDonald; Melinda J Wilkins; Jeffrey C Hageman
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

10.  Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections.

Authors:  Hui-min Neoh; Satoshi Hori; Mitsutaka Komatsu; Toyoko Oguri; Fumihiko Takeuchi; Longzhu Cui; Keiichi Hiramatsu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2007-10-30       Impact factor: 3.944

View more
  31 in total

1.  Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.

Authors:  B Edwards; K Milne; T Lawes; I Cook; A Robb; I M Gould
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

2.  Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods.

Authors:  Rodrigo M Paiva; Alice B Mombach Pinheiro Machado; Alexandre P Zavascki; Afonso L Barth
Journal:  J Clin Microbiol       Date:  2010-09-22       Impact factor: 5.948

3.  Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.

Authors:  Sheryl Zelenitsky; Noha Alkurdi; Zhanni Weber; Robert Ariano; George Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

4.  Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus.

Authors:  Mark C Kruzel; Cole T Lewis; Kerry J Welsh; Evan M Lewis; Nicola E Dundas; John F Mohr; Lisa Y Armitige; Audrey Wanger
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

5.  False daptomycin-nonsusceptible MIC results by Microscan panel PC 29 relative to Etest results for Staphylococcus aureus and enterococci.

Authors:  Elizabeth L Palavecino; Jacqueline M Burnell
Journal:  J Clin Microbiol       Date:  2012-10-17       Impact factor: 5.948

6.  Correlation of methicillin-resistant Staphylococcus aureus vancomycin minimal inhibitory concentration results by Etest and broth microdilution methods with population analysis profile: lack of Etest overestimation of the MIC.

Authors:  R Khatib; K Riederer; S Shemes; A C Musta; S Szpunar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-10       Impact factor: 3.267

7.  Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus.

Authors:  Franziska Ludwig; Becky Edwards; Timothy Lawes; Ian M Gould
Journal:  J Clin Microbiol       Date:  2012-08-01       Impact factor: 5.948

Review 8.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 9.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

10.  Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children?

Authors:  Natalia Jimenez-Truque; Isaac Thomsen; Elizabeth Saye; C Buddy Creech
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.